Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2025 update - PubMed
5 days ago
- #Cardiovascular Risk
- #Uric Acid
- #Hyperuricemia
- Hyperuricemia is linked to increased cardiovascular and renal risks, not just gout.
- Recent studies show adverse outcomes can occur at serum uric acid levels below classic thresholds, especially in high cardiovascular risk patients.
- A multidisciplinary European panel developed consensus recommendations based on literature review, including large cohort studies and randomized trials.
- Hyperuricemia is prevalent among individuals with hypertension, chronic kidney disease, obesity, diabetes, and cardiovascular disease.
- Elevated serum uric acid is independently associated with cardiovascular mortality, heart failure, stroke, and faster kidney disease progression.
- Randomized trials have not shown clear cardiovascular or renal benefits from routine urate-lowering therapy in asymptomatic hyperuricemia patients.
- The consensus recommends a risk-based, individualized approach to hyperuricemia management, including lifestyle measures and pharmacological therapy when needed.
- Hyperuricemia should be recognized as a significant cardiovascular and renal risk factor.
- Serum urate measurement can improve risk stratification in high-risk populations.
- Targeted urate-lowering strategies may be appropriate for high cardiovascular risk patients, symptomatic disease, or very high serum uric acid levels.
- Future trials are needed to determine if urate-lowering therapy can improve hard cardiovascular and renal outcomes.